Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · IEX Real-Time Price · USD
0.620
-0.044 (-6.70%)
At close: Jul 19, 2024, 4:00 PM
0.638
+0.018 (2.90%)
Pre-market: Jul 22, 2024, 7:35 AM EDT
Quoin Pharmaceuticals Employees
Quoin Pharmaceuticals had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,102,696
Market Cap
2.35M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4 | 0 | - |
Dec 31, 2022 | 4 | 0 | - |
Dec 31, 2021 | 4 | 2 | 100.00% |
Dec 31, 2020 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
cbdMD | 52 |
NovaBay Pharmaceuticals | 26 |
Windtree Therapeutics | 20 |
Catheter Precision | 14 |
InMed Pharmaceuticals | 13 |
Cyclacel Pharmaceuticals | 12 |
Heart Test Laboratories | 12 |
Phio Pharmaceuticals | 9 |
QNRX News
- 26 days ago - Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference - GlobeNewsWire
- 5 weeks ago - Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland - GlobeNewsWire
- 2 months ago - Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 - GlobeNewsWire
- 4 months ago - Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results - GlobeNewsWire
- 4 months ago - Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET - GlobeNewsWire
- 5 months ago - Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome - Accesswire
- 7 months ago - Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome - GlobeNewsWire